Chris Polman, Free University of Amsterdam
Abstract N Engl J Med 2006;345:899
Despite fears that natalizumab – which reduces progression in some categories of patients with multiple sclerosis – might increased the risk of a fatal viral infection, two-year randomised study finding have now given some reassurance that patients with relapsing disease can be treated.
[audio:https://www.audiomedica.com/podcasting/news/chris_polman.mp3]
Audio Journal of Medicine – July 20th 20 Jul, 2006 Audio Journal of Medicine: Single Embryo Transfer: Just as High Live Birth Rates as Double Transfer, But Without Risks 14 Aug, 2007 Audio Journal of Medicine: Circulating Markers Herald Onset of Preeclampsia 8 Jan, 2007 Audio Journal of Medicine – reporting from Annual Meeting of the European Society of Human Reproduction and Embryology, Prague, 18th – 21st June, 2006 21 Jun, 2006 
COVID-19 Co-Morbidity Risks Quantified from Three Continents SurveyMay 28, 2020
Ultrahypofractionated Radiation Just As Effective for Prostate CancerMay 16, 2018
First evidence that genome editing made patients with AIDS more resistant to HIVMarch 8, 2014Anticoagulation with warfarin can be beneficial in patients with atrial fibrillation and chronic kidney disease.March 7, 2014Prostate cancer: Adult exposure to bisphenol-A linked to prostate cancer riskMarch 6, 2014